Tozaro raises €6.9 million to transform cell and gene therapy manufacturing
UK-based startup Tozaro has secured €6.9 million in fresh funding to advance its platform aimed at dramatically reducing the cost and complexity of producing cell and gene therapies. The investment will support technology development, regulatory readiness and early commercial partnerships with biopharmaceutical manufacturers.
A platform built to tackle manufacturing bottlenecks
Cell and gene therapies promise life-changing treatments for cancers, rare diseases and inherited disorders, but their adoption is constrained by high production costs, long lead times and limited manufacturing capacity. Tozaro is developing an integrated platform that streamlines critical steps in the manufacturing workflow, from cell processing and viral vector handling to quality control and release testing.
By combining automated hardware with advanced bioprocessing protocols and embedded data analytics, the company aims to reduce manual interventions, cut error rates and increase batch consistency. This approach is designed to make advanced therapies more scalable and economically viable for both large pharmaceutical firms and emerging biotech players.
Funding to accelerate scale-up and partnerships
The new €6.9 million round will enable Tozaro to expand its engineering and process development teams, validate its platform in collaboration with early customers and prepare for larger-scale deployments in clinical and commercial settings. The startup plans to focus initially on indications where demand for manufacturing capacity is most acute, such as autologous cell therapies and high-value gene-modified treatments.
Industry observers see growing investor interest in technologies that address the infrastructure and cost challenges surrounding advanced therapies. By targeting the manufacturing layer rather than individual drug candidates, Tozaro positions itself as an enabling player in a market expected to grow rapidly as more therapies receive regulatory approval.
Implications for access and affordability
If successful, Tozaro‘s platform could help lower production costs and shorten time-to-patient for complex biological treatments, potentially improving access for health systems and patients worldwide. As payers scrutinize the high price tags associated with one-time curative therapies, technologies that can meaningfully reduce manufacturing costs are likely to play a critical role in shaping the next phase of the cell and gene therapy industry.